Literature DB >> 33343247

Treatment-Resistant Schizophrenia.

Peter F Buckley1.   

Abstract

Although, gratifyingly, research on the treatment of schizophrenia has increasingly focused on first-episode and prodromal patient populations, it is still recognized that many patients with more chronic illnesses exhibit a suboptimal response to treatments. This suboptimal response with continuation of symptoms is represented in the term treatment-resistant schizophrenia (TRS). This article addresses contemporary definitions as well as updated guidelines for patients with TRS.
Copyright © by the American Psychiatric Association.

Entities:  

Year:  2020        PMID: 33343247      PMCID: PMC7725152          DOI: 10.1176/appi.focus.20200025

Source DB:  PubMed          Journal:  Focus (Am Psychiatr Publ)        ISSN: 1541-4094


  19 in total

1.  Generation of refractory schizophrenia patient-derived induced pluripotent stem cell line UJSi001-A.

Authors:  Jing Sun; Xiaoya Zhang; Qijie Cong; Cong Wang; Dong Chen; Yincheng Wang; Xiaowen Wang; Zhenghui Yi; Shengying Qin
Journal:  Stem Cell Res       Date:  2019-05-09       Impact factor: 2.020

2.  Continuation Electroconvulsive Therapy for Patients With Clozapine-Resistant Schizophrenia: A Pilot Study.

Authors:  Raphael J Braga; Majnu John; Nina R Schooler; Samuel H Bailine; Chitra Malur; Alan Mendelowitz; Georgios Petrides
Journal:  J ECT       Date:  2019-09       Impact factor: 3.635

3.  Clozapine Combination and Augmentation Strategies in Patients With Schizophrenia -Recommendations From an International Expert Survey Among the Treatment Response and Resistance in Psychosis (TRRIP) Working Group.

Authors:  Elias Wagner; John M Kane; Christoph U Correll; Oliver Howes; Dan Siskind; William G Honer; Jimmy Lee; Peter Falkai; Thomas Schneider-Axmann; Alkomiet Hasan
Journal:  Schizophr Bull       Date:  2020-12-01       Impact factor: 9.306

4.  Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology.

Authors:  Thomas Re Barnes; Richard Drake; Carol Paton; Stephen J Cooper; Bill Deakin; I Nicol Ferrier; Catherine J Gregory; Peter M Haddad; Oliver D Howes; Ian Jones; Eileen M Joyce; Shôn Lewis; Anne Lingford-Hughes; James H MacCabe; David Cunningham Owens; Maxine X Patel; Julia Ma Sinclair; James M Stone; Peter S Talbot; Rachel Upthegrove; Angelika Wieck; Alison R Yung
Journal:  J Psychopharmacol       Date:  2019-12-12       Impact factor: 4.153

5.  Psychiatrists' attitude towards the use of clozapine in the treatment of refractory schizophrenia: A nationwide survey.

Authors:  Essam Daod; Amir Krivoy; Gal Shoval; Salman Zubedat; John Lally; Limor Vadas; Abraham Weizman; Alon Reshef; Boaz Bloch
Journal:  Psychiatry Res       Date:  2019-03-19       Impact factor: 3.222

6.  Successful treatment of clozapine-nonresponsive refractory hallucinations and delusions with pimavanserin, a serotonin 5HT-2A receptor inverse agonist.

Authors:  Henry A Nasrallah; Rissa Fedora; Robert Morton
Journal:  Schizophr Res       Date:  2019-03-02       Impact factor: 4.939

Review 7.  The Gut Microbiome and Treatment-Resistance in Schizophrenia.

Authors:  Mary V Seeman
Journal:  Psychiatr Q       Date:  2020-03

8.  The impact of clozapine initiation and cessation on psychiatric hospital admissions and bed days: a mirror image cohort study.

Authors:  D Siskind; T Reddel; J H MacCabe; S Kisely
Journal:  Psychopharmacology (Berl)       Date:  2019-02-04       Impact factor: 4.530

9.  Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study.

Authors:  René S Kahn; Inge Winter van Rossum; Stefan Leucht; Philip McGuire; Shon W Lewis; Marion Leboyer; Celso Arango; Paola Dazzan; Richard Drake; Stephan Heres; Covadonga M Díaz-Caneja; Dan Rujescu; Mark Weiser; Silvana Galderisi; Birte Glenthøj; Marinus J C Eijkemans; W Wolfgang Fleischhacker; Shitij Kapur; Iris E Sommer
Journal:  Lancet Psychiatry       Date:  2018-08-13       Impact factor: 77.056

Review 10.  Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology.

Authors:  Oliver D Howes; Rob McCutcheon; Ofer Agid; Andrea de Bartolomeis; Nico J M van Beveren; Michael L Birnbaum; Michael A P Bloomfield; Rodrigo A Bressan; Robert W Buchanan; William T Carpenter; David J Castle; Leslie Citrome; Zafiris J Daskalakis; Michael Davidson; Richard J Drake; Serdar Dursun; Bjørn H Ebdrup; Helio Elkis; Peter Falkai; W Wolfgang Fleischacker; Ary Gadelha; Fiona Gaughran; Birte Y Glenthøj; Ariel Graff-Guerrero; Jaime E C Hallak; William G Honer; James Kennedy; Bruce J Kinon; Stephen M Lawrie; Jimmy Lee; F Markus Leweke; James H MacCabe; Carolyn B McNabb; Herbert Meltzer; Hans-Jürgen Möller; Shinchiro Nakajima; Christos Pantelis; Tiago Reis Marques; Gary Remington; Susan L Rossell; Bruce R Russell; Cynthia O Siu; Takefumi Suzuki; Iris E Sommer; David Taylor; Neil Thomas; Alp Üçok; Daniel Umbricht; James T R Walters; John Kane; Christoph U Correll
Journal:  Am J Psychiatry       Date:  2016-12-06       Impact factor: 18.112

View more
  1 in total

1.  A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia.

Authors:  C U Correll; Ofer Agid; Benedicto Crespo-Facorro; Andrea de Bartolomeis; Andrea Fagiolini; Niko Seppälä; Oliver D Howes
Journal:  CNS Drugs       Date:  2022-06-27       Impact factor: 6.497

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.